FDA "Breakthrough" Ruling on Magic Mushrooms, Explained by Scientists

Inverseby Peter Hess10/25/2018

...Kelan Thomas, Pharm.D., an associate professor of clinical sciences at Touro University
California, co-authored a Journal of Psychoactive Drugs review of psilocybin-assisted therapy in 2017, in which he and his team predicted
the compound’s role in the future of psychiatry.

“I was very surprised that the FDA has already granted Breakthrough Therapy designation
just two months after they approved the study design,” Thomas tells Inverse. “Usually the FDA wants to evaluate data from the drug sponsor’s phase 2b trials
before granting Breakthrough Therapy designation, but perhaps data from the previous
psilocybin clinical trials that were summarized in my 2017 review article were sufficient
evidence.”